The Effect of Obesity Management on Body Image in Patients Seeking Treatment at Medical Centers

Grave, Riccardo Dalle; Cuzzolaro, Massimo; Calugi, Simona; Tomasi, Franco; Temperilli, Flavia; Marchesini, Giulio

doi:10.1038/oby.2007.275

Cited by 40 publications

(23 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These reductions are likely to be clinically beneficial given compelling evidence that 5-10% weight loss is associated with improved glucose and lipid metabolism, lower incidence of T2D, improved psychosocial outcomes, and reductions in several other weight-related comorbidities (hypertension, sleep apnea, osteoarthritis) [12,21,22,23,24,25]. …”

Section: Discussionmentioning

confidence: 99%

Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis

Roux

Aroda²,

Hemmingsson³

et al. 2017

Obes Facts

View full text Add to dashboard Cite

Objective: To investigate whether the efficacy and safety of liraglutide 3.0 mg differed between two subgroups, BMI 27 to <35 and BMI ≥ 35 kg/m², in individuals without and with type 2 diabetes (T2D). Methods: A post-hoc analysis of two 56-week, randomized, double-blind, placebo-controlled trials (SCALE Obesity and Prediabetes; SCALE Diabetes). Subgroup differences in treatment effects of liraglutide 3.0 mg were evaluated by testing the interaction between treatment group and baseline BMI subgroup. Results: Significantly greater weight loss (0-56 weeks) was observed with liraglutide 3.0 mg versus placebo in all patient groups while on treatment. There was no evidence that the weight-lowering effect of liraglutide 3.0 mg differed between BMI subgroups (interaction p > 0.05). Similarly, for most secondary endpoints significantly greater improvements were observed with liraglutide 3.0 mg versus placebo, with no indication treatment effects differing between subgroups. The safety profile of liraglutide 3.0 mg was broadly similar across BMI subgroups. Conclusion: This post-hoc analysis did not indicate any differences in the treatment effects, or safety profile, of liraglutide 3.0 mg for individuals with BMI 27 to <35 or ≥35 kg/m². Liraglutide 3.0 mg can therefore be considered for individuals with a BMI of ≥35 as well as for those with a BMI of 27 to <35 kg/m².

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis

Roux

Aroda²,

Hemmingsson³

et al. 2017

Obes Facts

View full text Add to dashboard Cite

show abstract

“…Indeed, data from randomized controlled trials of structured group weight-loss interventions indicate that, on average, 80% of patients who enrol in such programmes go on to complete the treatment (Wadden & Butryn, 2003), with completers achieving a mean weight loss of 8e10% of their initial body weight within roughly 30 weeks (Wadden & Butryn, 2003). According to the 2013 Guidelines for the Management of Overweight and Obesity in Adults (Jensen et al, 2014), this amount of weight loss can be considered successful (i.e., in line with a 5e10% reduction of initial weight), being associated with a significant reduction in the incidence of type-2 diabetes (Knowler et al, 2002), and clinical improvements in weightrelated medical comorbidities (e.g., sleep apnoea, diabetes, hypertension, hyperlipidaemia) (Jensen et al, 2014), and psychosocial outcomes (e.g., mood, quality of life, and body image) (Dalle Grave et al, 2007;Faulconbridge et al, 2012;Fontaine, Barofsky, Bartlett, Franckowiak, & Andersen, 2004).…”

Section: Introductionmentioning

confidence: 97%

The influence of cognitive factors in the treatment of obesity: Lessons from the QUOVADIS study

Grave

Calugi

Marchesini

2014

Behaviour Research and Therapy

Self Cite

View full text Add to dashboard Cite

“…Recently, Riva and colleagues proposed the allocentric lock hypothesis (Gaudio & Riva, 2013;Riva, 2007Riva, , 2011Riva & Gaudio, 2012), suggesting that ED and obesity may be the outcome of a primary disturbance in the way the body is experienced and remembered: Individuals with these disorders may be locked into an allocentric (observer view) image schema of their body that is no longer updated by contrasting egocentric representations driven by perception. Although this hypothesis may appear more suitable as a description of eating disorders than of obesity, research does support a lack of a direct correlation between weight loss and body image (Sorbara & Geliebter, 2002;Dalle Grave et al, 2007).…”

Section: Discussionmentioning

confidence: 95%

Virtual Reality Based Treatments in Eating Disorders and Obesity: A Review

Ferrer-García

Gutiérrez-Maldonado

Riva

2013

J Contemp Psychother

View full text Add to dashboard Cite

Since the late 1990s the use of virtual reality (VR) has expanded in the field of mental disorders. During this time, several VR-based applications have been developed for the treatment of eating disorders (ED) and obesity. Both these pathologies involve disturbances related to eating behavior, weight, and body image. Although effective and well-established protocols are now available for the treatment of ED and obesity, relapses are frequent and a proportion of patients do not improve after intervention. In this context, VR has been shown to be a useful technology for enhancing traditional cognitive-oriented therapies. The main objective of this review was therefore to examine the evidence regarding the efficacy of VR-based treatments as a component of therapeutic interventions for ED and obesity. To this end, three databases (PsycInfo, Medline, and PsycArticles) were searched for the period 1986 to 2012. Only research articles and case studies were selected. Although several methodological deficiencies were detected in the reviewed studies, there is fair evidence for the effectiveness of VR-based treatments in ED and obesity. VR-based interventions usually combine exposure to VR environments with cognitive therapies. The VR component seems to be especially suitable for reducing body image disturbances, such as body image dissatisfaction, and for increasing self-esteem and self-efficacy. The rationale for the use of VR in these areas is also presented and discussed.

show abstract

The Effect of Obesity Management on Body Image in Patients Seeking Treatment at Medical Centers

Abstract: Obesity treatment, even with a modest degree of weight loss, is associated with a significant improvement of body image, in both females and males. This effect depends mainly on psychological factors, not on the amount of weight loss.

Cited by 40 publications

References 40 publications

Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis

Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis

The influence of cognitive factors in the treatment of obesity: Lessons from the QUOVADIS study

Virtual Reality Based Treatments in Eating Disorders and Obesity: A Review

Contact Info

Product

Resources

About